Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration

Journal of Nuclear Medicine

Volumn 53, Issue 5, 2012, Pages 749-753

  Melis, Marleen ^a   Valkema, Roelf ^a   Krenning, Eric P ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Amifostine; Kidney; PRRT; Tumor protection; WR 1065

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; CUBILIN; MEGALIN; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TETRAXETAN; TETRAXETAN TYROSINE 3 OCTREOTATE IN 111; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RETENTION; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY PARENCHYMA; NEPHROTOXICITY; NONHUMAN; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIOISOTOPE THERAPY; RAT; RAT STRAIN; RENAL PROTECTION;

AMIFOSTINE; ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; COORDINATION COMPLEXES; GENE EXPRESSION REGULATION, NEOPLASTIC; ISOTOPE LABELING; KIDNEY; MALE; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIATION-PROTECTIVE AGENTS; RATS; RECEPTORS, SOMATOSTATIN;

EID: 84860769767     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.098665     Document Type: Article

References (46)

1. Chiba M, Ishii Y, Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J. 2009;11:262-276.
2. Nies AT, Schwab M, Keppler D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol. 2008;4:545-568. (Pubitemid 351890738)
3. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol. 2005;45: 689-723. (Pubitemid 40261822)
4. Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet. 2008;23:223-235.
5. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: Implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009;5:703-729.
6. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81:194-204. (Pubitemid 46174816)
7. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 2007;453:643-659. (Pubitemid 46192536)
8. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006;27:425-446. (Pubitemid 43363338)
9. König J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:432-443.
10. Sissung TM, Gardner ER, Gao R, Figg WD. Pharmacogenetics of membrane transporters: A review of current approaches. Methods Mol Biol. 2008;448:41-62.
11. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxelinduced leukopenia. Cancer Sci. 2008;99:967-972. (Pubitemid 351997599)
12. Bergström M, Grahnen A, Langstrom B. Positron emission tomography microdosing: A new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol. 2003;59:357-366. (Pubitemid 37214939)
13. Riemann B, Schafers KP, Schober O, Schafers M. Small animal PET in preclinical studies: Opportunities and challenges. Q J Nucl Med Mol Imaging. 2008;52:215-221.
14. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7:591-607. (Pubitemid 351927724)
15. Takashima T, Nagata H, Nakae T, et al. Positron emission tomography studies using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin methyl ester for the evaluation of hepatobiliary transport. J Pharmacol Exp Ther. 2010;335: 314-323.
16. Suzuki M, Doi H, Björkman M, et al. Rapid methylation on carbon frameworks leading to the synthesis of a PET tracer capable of imaging a novel CNS-type prostacyclin receptor in living human brain. Trends Analyt Chem. 2004;23:595-607. (Pubitemid 39232082)
17. Björkman M, Andersson Y, Doi H, et al. Synthesis of 11C/13C-labelled prostacyclins. Acta Chem Scand. 1998;52:635-640.
18. Kim DC, Sugiyama Y, Satoh H, Fuwa T, Iga T, Hanano M. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci. 1988;77:200-207.
19. Li N, Bi YA, Duignan DB, Lai Y. Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol Pharm. 2009;6:1180-1189.
20. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311:139-146. (Pubitemid 39287793)
21. Maeda K, Kambara M, Tian Y, Hofmann AF, Sugiyama Y. Uptake of ursodeoxycholate and its conjugates by human hepatocytes: Role of Na(1)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and OATP1B3 (OATP8). Mol Pharm. 2006;3:70-77. (Pubitemid 43331753)
22. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34: 1229-1236.
23. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008; 36:2014-2023.
24. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn. 1981;4:879-885. (Pubitemid 12174128)
25. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093-1095. (Pubitemid 23211439)
26. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36:164-172. (Pubitemid 34700774)
27. Kohno HHB, Tsuchiya T, Kubo H, Kobayashi Y. Pharmacokinetics of ifampicin. Rinsyo Yakuri. 1982;13:403-412.
28. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003;304:223-228. (Pubitemid 36008932)
29. Nakanishi T, Shibue Y, Fukuyama Y, et al. Quantitative time-lapse imaging (QTLI)-based analysis of drug-drug interaction mediated by hepatobiliary transporter, multidrug associated protein 2, in sandwich-cultured rat hepatocytes. Drug Metab Dispos. 2011;39:984-991.
30. Yoshida K, Maeda K, Sugiyama Y. Prediction of the degree of transportermediated drug-drug interactions involving OATP substrates based on in vitro inhibition studies. Clin Pharmacol Ther. In press.
31. Ghibellini G, Leslie EM, Pollack GM, Brouwer KL. Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: Integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res. 2008;25: 1851-1860.
32. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127-145.
33. Shaw LM, Bonner H, Lieberman R. Pharmacokinetic profile of amifostine. Semin Oncol. 1996;23:18-22. (Pubitemid 26321667)
34. Kaldir M, Cosar-Alas R, Cermik TF, et al. Amifostine use in radiation-induced kidney damage: Preclinical evaluation with scintigraphic and histopathologic parameters. Strahlenther Onkol. 2008;184:370-375.
35. Capizzi R. Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol. 1996; 23:2-17. (Pubitemid 26321666)
36. Shaw LM, Bonner HS, Brown DQ. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos. 1994;22:895-902. (Pubitemid 24377365)
37. Koukourakis MI. Amifostine: Is there evidence of tumor protection? Semin Oncol. 2003;30:18-30. (Pubitemid 38120496)
38. Breeman WA, De Jong M, Visser TJ, et al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917-920. (Pubitemid 36734213)
39. Le Panse S, Verroust P, Christensen EI. Internalization and recycling of glycoprotein 280 in BN/MSV yolk sac epithelial cells: A model system of relevance to receptor-mediated endocytosis in the renal proximal tubule. Exp Nephrol. 1997;5:375-383. (Pubitemid 27475570)
40. Vegt E, Eek A, Oyen WJ, et al. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2010;37:226-234.
41. de Jong M, Breeman WA, Bernard BF, et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26:693-698. (Pubitemid 29338656)
42. Bachy CM, Fazenbaker CA, Kifle G, et al. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys. Oncology. 2004;67:187-193. (Pubitemid 39551700)
43. Bukowski RM. Amifostine (Ethyol): Dosing, administration and patient management guidelines. Eur J Cancer. 1996;32A:S46-S49.
44. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: The first selective-target and broad-spectrum radioprotector. Oncologist. 2007;12:738-747. (Pubitemid 47036208)
45. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys. 2003;57:794-802. (Pubitemid 37194307)
46. Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis. Int J Radiat Oncol Biol Phys. 2006;64:784-791. (Pubitemid 43183575)